ABSTRACT The effect of early and late nifedipine treatment on collateral blood flow and myocardial infarct size was investigated in 24 previously instrumented conscious dogs. Nifedipine was infused intravenously for 5 hr beginning 15 min (n = 9) and 3 hr (n = 6) after permanent occlusion of the midcircumflex coronary artery and compared with early and delayed vehicle treatment (controls; n = 9). Doses of nifedipine (90 to 168 ,gg/hr) were titrated to reduce mean arterial pressure by 5% to 10%.
cells might afford direct myocardial protection, since calcium overload appears to be important in the pathogenesis of irreversible damage.'-' Experimentally, nifedipine has been shown in the anesthetized and conscious dog to increase collateral flow regionally under ischemic conditions, 4 although this finding has not been universal.7 Nifedipine has been associated with improved short-term indexes of myocardial damage, including better regional and global ventricular function,"-" less electrocardiographic R wave loss,6 less depletion of myocardial adenosine triphosphate,'2 and delayed release of creatine kinase. Henry et al. 4 found that treatment with nifedipine in conscious dogs resulted in less marked depletion of creatine kinase at myocardial sites matched for the initial degree of ischemia. However, Geary et al. '3 found no myocardial protection in the anesthetized baboon, an animal known to have sparse native intercoronary collateral channels. 14, 1 ' This study was designed to assess the relative importance of collateral flow changes and direct actions of nifedipine not mediated by flow in protecting regional-131 ly ischemic myocardium. We used a conscious canine preparation in which infarct size was determined morphologically 7 days after coronary artery occlusion and related to the amount of myocardium initially "at risk," defined as the anatomic occluded vascular bed.'6 Treatment with nifedipine was purposely delayed for 3 hr in some of the animals to more closely mimic the therapeutic delay occurring in patients with myocardial infarction.
Methods
Instrumentation. Thirty-two mongrel dogs weighing 19 to 24kg were instrumented aseptically under pentobarbital general anesthesia through a left lateral thoracotomy. A mechanical snare was placed around the circumflex artery just past the first large marginal branch. Polyethylene catheters were placed in the external jugular vein, common carotid artery, and left atrium. The distal ends of the catheters and snare were brought out at the back of the neck through a subcutaneous tunnel. Penicillin (1,000,000 U) and streptomycin (1 g) were given intramuscularly and t6i¢ catheters were filled with 1000 IU of heparin.
Operative mortality rate was 8%.
Experiments. Ten days later the 30 surviving dogs were studied while conscious and standing in a support sling. Morphine (0.25 mg/kg) was given intramuscularly on arrival in the laboratory and was repeated intravenously 30 min later. The electrocardiogram and left atrial and aortic pressures (Statham P 23 Db) were recorded continuously.
Myocardial blood flow was measured by serial injections of radioactive microspheres, 7 to 10 gm in diameter, with polysorbate 80 added; spheres were labeled with 1251, "4Ce, 85Sr, 95Nb, or 46Sc (3M Co.). Standard techniques were used as described previously. 16 The first microspheres were given 30 min after intravenous morphine. Five minutes later coronary occlusion was established, and a second microsphere flow measurement was made 5 min later. No attempt was made to suppress ectopic activity. Three dogs died from ventricular fibrillation within the first 10 min.
Ten minutes after occlusion the dogs were randomly allocated to the early or late treatment group (treatment begun 15 min [n = 141 or 3 hr after occlusion [n = 13]). Treatment consisted of an intravenous infusion of nifedipine (n = 17; nine earlytreated and eight late-treated animals) or vehicle (n = 10; five early-treated and five late-treated animals). In nifedipine-treated dogs a loading dose of 20 to 40 ,ug/min was given for 3 min, followed by an infusion of 1.5 to 2.8 p.g/min, adjusted to reduce mean arterial pressure by 5% to 10% below the prenifedipine level but not below 90 mm Hg. The infusion system was covered with aluminum foil to prevent light inactivation of the drug. Vehicle (15% polyethylene glycol and 15% ethanol in water) was infused at an initial rate of 0.3 ml/min for 3 min, followed by 0.02 ml/min. In both the nifedipine and vehicle groups, total infusion time was 5 hr. At the end of infusion the pump was turned off for 10 to 20 min to verify persistent drug effect in the nifedipine group. In 13 dogs mean arterial pressure increased by an average 7% (5% to 13%), while in two dogs no change occurred.
Microsphere flow measurements were repeated 1 hr after the infusion was begun and again just before termination. In the late treatment group, an additional measurement was made 3 hr after occlusion before the infusion was started. Eight hours after occlusion all dogs were returned to their cages.
Seven days later the 18 surviving animals were brought back to the laboratory for hemodynamic recordings. They were then given a lethal dose of anesthetic and the hearts were removed. Delineation of the anatomic risk region. The size of the anatomic risk region, or occluded vascular bed, was measured by postmortem stereoscopic angiography, as previously described.'6 The coronary arteries were cannulated separately at their origins and injected simultaneously under controlled pressure (160 mm Hg) with a barium sulfate gelatin mass. Each heart was sliced into four or five transverse sections of equal width (I to 1.5 cm). The boundaries of the risk region were marked on each radiographed section by an observer who had no knowledge of the treatment given. The major coronary arterial branches were identified as originating from a normal vessel or from the circumflex artery distal to the occlusion. The course of each branch was followed from ring to ring and a mark was placed where the terminal ramifications of an occluded artery interdigitated with those of an unoccluded vessel. Good interobserver reproducibility with this technique has been shown previously. '16 Measurement of infarct size. The formalin-fixed heart slices were dissected free of the atria, right ventricle, large epicardial vessels, and fat. The left ventricular rings were weighed and traced on clear acetate sheets. Areas of infarction were identified by gross inspection and marked on each tracing by an observer without knowledge of the treatment given. The outlines of the occluded bed were transferred to the tracings after superimposition on corresponding radiographs and alignment by means of natural (papillary muscles and cavity shape) and metallic markers. Areas of the left ventricular rings, risk regions, and infarcts were measured by planimetry, and masses of infarct and risk region were calculated by multiplying the appropriate area ratios by the weight of each ring and summing the values for the whole heart.
The spatial distribution of infarct within the risk region was determined in the control and nifedipine-treated animals. Measurements were made along the endocardium and epicardium at the lateral borders of the risk region and at four equal intervals within the infarct; corresponding measurements from the top and bottom surfaces of each ring were averaged. '7 Measurement of regional myocardial blood flow. Sampling for regional myocardial blood flow was made transmurally (0.5 to 1.5 g) in the center of the infarct, in the normallooking tissue within the risk region on either side of the infarct and in the nonischemic anterior wall. Samples were divided into inner and outer halves, weighed, and counted for radioactivity with the reference blood samples in a scintillation counter (Packard 5986) at appropriate energy windows. Myocardial blood flow (ml/min/g) was calculated by standard methods. 16 Blood flows for each region were found by pooling appropriate myocardial samples. All flow values were corrected for true and apparent microsphere loss. '7 18 The preocclusion content of microspheres in each ischemic region expressed relative to that in the nonischemic area was used to quantify the combined effects of microsphere loss, local edema, hemorrhage, and inflammatory cell infiltrate. Underestimation of flow due to these factors ranged from 21% in the endocardium of the infarct center to 8% in the epicardium of the noninfarcted risk region.
Statistical analysis. Student's t tests for paired and unpaired data were used for statistical computations between groups. Repeated measures analysis of variance with orthogonal contrast was used to analyze changes in sequential postocclusion flows in different regions within and between the two groups. Multiple linear regression analysis was used to account for the effects of both risk region and collateral flow on infarct size. The significance of the difference between treated and control groups in the multiple linear regression was tested by pooling data from all animals and using "treated" or "control" as a CIRCULATION 132 
Results
The 27 dogs surviving 10 min of coronary occlusion were randomly treated with either nifedipine (n = 17) or vehicle (n = 10). Nine dogs (five treated with nifedipine and four with vehicle) died over the 7 days after coronary occlusion. Of the nine, six (three treated with nifedipine and three with vehicle) survived more than 24 hr and had clearly defined infarcts. These six dogs along with the 18 that survived 7 days were included in the analysis and form the basis of this report; nine were treated with vehicle (four early-treated and five late-treated animals) and 15 with nifedipine (nine early-treated and six late-treated animals). The difference in survival to 7 days (vehicle, 6/10; nifedipine, 12/17) was not statistically significant.
Hemodynamics. The hemodynamic changes are summarized in table 1. Preocclusion heart rate, mean arterial pressure, and mean left atrial pressure were similar in both groups. After coronary occlusion, heart rate and left atrial pressure increased significantly but mean arterial pressure did not change. These changes were maintained at 1 hr after treatment in the control dogs. At 5 hr in the control group, heart rate was increased further from 116 to 131 beats/min (p = .025) and mean arterial pressure was reduced from 115 to 107 mm Hg (p = .04). In the nifedipine group, the drug produced a 9% reduction in mean arterial pressure at 1 hr after treatment from 126 to 115 mm Hg (p < .005), while at 5 hr after treatment the mean arterial pressure was reduced by 17% (to 104 mm Hg; p < .001). The decrease in mean arterial pressure was similar in the early-and late-treated nifedipine groups. After nifedipine, left atrial pressure was reduced at 1 hr (from 10 to 7 mm Hg; p < .005) and at 5 hr after treatment (to 9 mm Hg; p < .05). There was a significant increase in heart rate at 1 hr after nifedipine treatment (123 to 137 beats/min; p < .05) and heart rate remained significantly higher 5 hr after treatment ( 139 beats/min; p < .05).
Effect of nifedipine on infarct size. In both the earlyand late-treated subgroups, nifedipine significantly reduced infarct size expressed as a percent of the risk A wide range of infarct and risk region sizes were seen in both groups, but the mass of the infarct was always related to the mass of the risk region (figure 2). The slope of the linear regression for the control group was greater (0. 82 vs 0. 68), although the difference was not statistically significant. Data for nifedipine-treated dogs are shifted downward in figure 2, indicating smaller infarcts over a broad range of risk region sizes. Figure 3 shows the spatial geometry of the infarct LN within the risk region in the control group and the two nifedipine-treated groups. In all three groups, the infarct and risk region were larger in basal and middle rings of the left ventricle and smaller toward the apex.
RCT
The percent of risk region infarcted was also greater in KON basal than in apical rings in the three groups. after 1 hr of infusion but did increase after 5 hr in the outer layers of the noninfarcted risk region. In the outer layers of the infarct center and noninfarcted risk nonischemic region, epicardial flow increased at 5 hr region. In the nifedipine-treated group, collateral flow in the control group, while endocardial and epicardial was significantly increased after 1 hr of treatment and flows were increased at 1 and 5 hr in the nifedipine continued to increase over the 5 hr infusion period in group. Trend analysis, however, failed to show a stathe outer layer of the infarct center and in the inner and tistically significant difference between control and ni- fedipine-treated groups in sequential blood flows after occlusion. AS NIFEDIPINE reduced in the nifedipine-treated group, as indicated by the downward shift of the curve.
In figure 6 , collateral flow 1 hr after the beginning of the infusion was related to the amount of infarcted myocardium within the risk region. This relationship provides insight into the mechanism of myocardial protection by nifedipine. Three dogs with the highest collateral flow (epicardial flows >0.6 ml/min/g) received nifedipine and less than 35% of myocardium within the risk zone was infarcted. Most of the other nifedipine-treated dogs also demonstrated smaller amounts of infarcted tissue (points shifted to the left) even though collateral flow was comparable to that in control dogs. This suggests that protection by nifedipine was related in part to mechanisms other than increased collateral flow.
Multiple linear regression analysis. Because postocclusion collateral flow and risk region size were both correlated with infarct size, we calculated the multiple linear regression equation for the control group (infarct = 3.6 + 0. figure 7 . The diagram shows that infarcts were smaller for a given risk region size and a given level of collateral flow after nifedipine treatment (differences between regression planes, p < .001). The difference was smallest when collateral flow was low, and for a collateral flow of zero there was essentially no difference. Conversely, the difference between the planes was greatest when collateral flow was high. lateral flow and the failure of collateral flow to increase after nifedipine treatment, although the relationship was not absolute.
Discussion
Our results indicate that nifedipine, given for 5 hr in a dose sufficient to reduce mean arterial pressure 5% to 10%, reduces infarct size by about 30% after permanent coronary artery occlusion in the conscious dog. Benefit was seen when treatment was begun 15 min after occlusion and also when it was delayed for 3 hr to more closely approximate the time delay that occurs in patients admitted with acute myocardial infarction. Collateral flow, particularly to the subepicardial layer of the ischemic region, was increased after nifedipine but was also increased in dogs given vehicle; the mean difference between the treated and control groups was not statistically significant. Nevertheless, of four dogs with subepicardial collateral flow greater than 0.5 ml/ min/g 1 hr after the infusion was begun, all were from the nifedipine group and all showed myocardial protection (figure 6). Nifedipine therefore appeared to increase collateral flow in a subset of the treated group and the increased flow probably contributed to at least part of the myocardial protection observed in these animals. In the remaining 10 nifedipine-treated dogs, flow was less than 0.5 ml/min/g and comparable to the animals receiving vehicle; six of these 10 also demon-138 strated protection, suggesting that direct effects of nifedipine not mediated by flow contributed to myocardial salvage.
Methodologic considerations. Collateral flow was determined in relatively large myocardial samples taken from the center of the infarct zone and the noninfarcted region within the occluded bed lateral to the infarct. Although care was taken to exclude tissue from outside the occluded bed, absolute precision was probably not possible because of the convoluted nature of the border separating vascular territories' 20 and the shift in position of this border between top and bottom surfaces of a ventricular slice. "Contamination" of ischemic zone samples with myocardium from nonoccluded vascular beds could lead to false conclusions about changes in collateral flow if flow to nonischemic myocardium were to change simultaneously.2' In our study, flow increased in subepicardial layers throughout the occluded bed after nifedipine, but these findings must be interpreted cautiously since flow also increased about 40% in nonischemic regions. From table 3 it can be calculated that apparent increases in collateral flow of the amount observed could occur if samples from the center zone and noninfarcted risk zone contained 8% and 23% of nonischemic tissue, respectively. Although we do not believe that contamination of this extent occurred, especially in samples from the center zone, the possibility cannot be entirely dismissed.
In our study infarct size was correlated with both occluded bed size and early postocclusion collateral flow in the control and nifedipine-treated groups (figures 2 and 5). We therefore used multiple linear regression analysis to describe infarct size in terms of both variables simultaneously. The multiple correlation coefficients obtained (.94 for control, .87 for nifedipine) were higher than those for either variable alone. Because of the high multiple correlation coefficient for the control group, it was possible to use the control equation to calculate an expected infarct size for each dog in the nifedipine group, given its occluded bed size and early postocclusion collateral flow. The presence or absence of myocardial protection could then be ascertained in each treated dog by comparing the predicted against the actual measured infarct size (table 4) . This approach avoids the overly simplistic analysis that is usually performed in which mean differences between treated and control groups are compared but the variability in response between animals is ignored.
Regional myocardial blood flow. As in our study, all previous reports have described an increase in blood flow to nonischemic myocardium after nifedipine.46 This increase is probably the result of primary dilata-CIRCULATION LABORATORY INVESTIGATION-CORONARY ARTERY DISEASE tion of the small coronary arteries leading to a decrease in coronary vascular resistance. Although heart rate was increased in our study, arterial pressure and left ventricular diastolic pressure were reduced, and the resulting net increase in oxygen demands appeared to be too small to account for the magnitude of the observed increase in blood flow.
Although the mean increase in collateral flow after nifedipine was not statistically greater than control values in our study, a subgroup of animals appeared to demonstrate an important increase in flow to ischemic myocardium. Previous studies have shown a somewhat variable effect of nifedipine on collateral blood flow. Most investigators have demonstrated an increase, except in regions with very low initial flow4 or when perfusion pressure is allowed to fall more than about 20%.6 However, Weintraub et al." did not find any significant change in ischemic zone flow after either intracoronary or intravenous nifedipine (with minimal change in blood pressure or heart rate) in anesthetized dogs with severe coronary artery stenosis. The most likely mechanism for an increase in collateral flow is direct dilatation of the arteries in nonischemic zones providing the source for collateral flow. Alternatively, nifedipine could dilate the collaterals themselves or the arteries within the ischemic zone,22 or it could promote collateral flow by reducing left ventricular filling pressure, thereby reducing extravascular compressive forces on the subendocardium.
Effect of nifedipine on myocardial necrosis. Although several studies have found improvement in short-term indexes of myocardial injury with nifedipine, including better global and regional function,8'" less depletion of myocardial adenosine triphosphate, 12 and less R wave loss,6 few studies have examined the effect of nifedipine on the extent of completed necrosis. Henry et al. 4 found that infusion of the drug for 23.5 hr, beginning 30 min after occlusion of the anterior descending coronary artery, resulted in less depletion of creatine kinase at 24 hr at myocardial sites matched for their initial degree of ischemia, even those with very low initial flow (<0.1 ml/min/g). In contrast, Geary et al. 13 showed no decrease in infarct size with nifedipine in the baboon after 2 hr of occlusion of the anterior descending coronary artery followed by reflow. Nifedipine was given in this study for 5 hr, beginning 1 hr before occlusion, in a dose that reduced mean arterial pressure by 8%. Although collateral flow was not measured, the baboon is known to have a small native collateral network'4' '5 and the ineffectiveness of nifedipine was attributed by the authors by the severity of ischemia. In our study, a 5 hr infusion of nifedipine reduced mean infarct size about 30%. Dogs with higher levels of collateral flow appeared to have better myocardial protection while those with low flow had little or none (figure 7). The intensity of ischemia therefore appears to modify the protective effects of nifedipine; at very low flows nifedipine may be unable to alter the progression from reversible to irreversible injury.
Interval between coronary occlusion and treatment. A number of studies have characterized the time course over which myocardial cell death occurs after coronary occlusion.19 23 Myocardial necrosis begins about 20 min after occlusion of the circumflex coronary artery in anesthetized dogs and is almost complete by 3 to 4 hr.24 However, in anesthetized animals, exaggerated myocardial oxygen demands would be expected to initiate necrosis more rapidly than in conscious animals for a given reduction in blood flow. In conscious dogs, infarct size (as percent of anatomic risk region) measured 72 hr after coronary occlusion was shown to be significantly smaller after 4 hr of occlusion followed by reflow than after 72 hr of occlusion (32.3% vs 49. 9%).2A Therefore, in conscious dogs, myocardial salvage should still be possible at 4 hr after coronary occlusion, particularly in areas of only moderately reduced flow.
Our results indicate that nifedipine exerts a protective effect even when treatment is delayed for 3 hr. In our study, reduction of infarct size was slightly greater in dogs treated late compared with those treated early, but this result is almost certainly an artifact related to the small number of dogs in each group. Three of the four animals unprotected by nifedipine were from the early treatment group, tending to reduce the average myocardial salvage for this group and obscuring the expected difference between infarct size in the earlyand late-treated groups. Although our results clearly show a protective effect of nifedipine with both early and late treatment, we do not believe that the degree of protection can be reliably compared.
Mechanism of myocardial protection by nifedipine. Although an increase in collateral flow appears to account for part of the myocardial protection observed with nifedipine, direct mechanisms not mediated by flow probably also play a role. In ATPases. An increase in calcium might be responsible for undissociated cross-bridges, producing ischemic myocardial rigor. An excess of calcium activates membrane phospholipase with subsequent formation of the detergent lysophosphatide, and this activation of endogenous phospholipase could be one possible mechanism for sarcolemmal damage. Nifedipine has been shown to improve mechanical performance and prevent ATP depletion in the perfused rabbit heart when given during a period of severe global ischemia.'2 These beneficial effects have been correlated with reduced tissue and mitochondrial calcium levels, suggesting a specific effect of this agent on calcium transport across the slow calcium channels in ischemic cells. In addition, nifedipine has recently been shown to interfere with the release of calcium from intracellular sites, further supporting its usefulness for circumventing calcium overload during ischemia. Further investigations will be required to elucidate the role of calcium in ischemic cell death and the precise mechanism of the beneficial action of nifedipine on ischemic myocardium. myocardial blood flow during vasodilation depends on criteria used to identify ischemic myocardium. 
